Pharmacologic management of atrial fibrillation

被引:10
作者
Riley, RD
Pritchett, ELC
机构
[1] DUKE UNIV, MED CTR, DEPT MED, DIV CLIN PHARMACOL, DURHAM, NC 27710 USA
[2] DUKE UNIV, MED CTR, DEPT MED, DIV CARDIOL, DURHAM, NC 27710 USA
[3] SINAI HOSP, DEPT MED, BALTIMORE, MD 21215 USA
关键词
antiarrhythmic drugs; thromboembolism; stroke; defibrillation;
D O I
10.1111/j.1540-8167.1997.tb00841.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pharmacologic Management of AF. In an era when many electrophysiologic problems are routinely with invasive procedures or implantable devices, drugs remain the cornerstones of treatment for atrial fibrillation. Atrial fibrillation may present as an episodic rhythm in patients who are primarily in sinus rhythm or it may be manifested as rhythm disorder that is permanent. Patients who appear to have an episodic rhythm disorder may be found to be in atrial fibrillation permanently when followed for long periods of time, and prognosis in the two forms is similar. It is, therefore, useful to consider them different manifestations in the same spectrum of disease. This review will address pharmacologic approaches designed to: (1) slow ventricular response; (2) restore sinus rhythm; (3) reduce occurrences of atrial fibrillation; and (4) prevent thromboembolic complications. Nonpharmacologic approaches to treating atrial fibrillation will be briefly reviewed.
引用
收藏
页码:818 / 829
页数:12
相关论文
共 96 条
  • [1] PREDICTORS OF THROMBOEMBOLISM IN ATRIAL-FIBRILLATION .1. CLINICAL-FEATURES OF PATIENTS AT RISK
    ANDERSON, DC
    ASINGER, RW
    NEWBURG, SM
    FARMER, CC
    WANG, K
    BUNDLIE, SR
    KOLLER, RL
    JAGIELLA, WM
    KREHER, S
    JORGENSEN, CR
    SHARKEY, SW
    FLAKER, GC
    WEBEL, R
    NOLTE, B
    STEVENSON, P
    BYER, J
    WRIGHT, W
    CHESEBRO, JH
    WIEBERS, DO
    HOLLAND, AE
    MILLER, DM
    BARDSLEY, WT
    LITIN, SC
    MEISSNER, I
    ZERBE, DM
    MCANULTY, JH
    MARCHANT, C
    COULL, BM
    FELDMAN, G
    HAYWARD, A
    GANDARA, E
    MACMILLAN, K
    BLANK, N
    LEONARD, AD
    KANTER, MC
    ISENSEE, LM
    QUIROGA, ES
    PRESTI, CH
    TEGELER, CH
    LOGAN, WR
    HAMILTON, WP
    GREEN, BJ
    BACON, RS
    REDD, RM
    CADELL, DJ
    GOMEZ, CR
    JANOSIK, DL
    LABOVITZ, AJ
    KELLEY, RE
    CHAHINE, R
    [J]. ANNALS OF INTERNAL MEDICINE, 1992, 116 (01) : 1 - 5
  • [2] ANDERSON DC, 1992, ANN INTERN MED, V116, P6
  • [3] OCCURRENCE OF VENTRICULAR ARRHYTHMIAS IN PATIENTS RECEIVING ACUTE AND CHRONIC INFUSIONS OF MILRINONE
    ANDERSON, JL
    ASKINS, JC
    GILBERT, EM
    MENLOVE, RL
    LUTZ, JR
    [J]. AMERICAN HEART JOURNAL, 1986, 111 (03) : 466 - 474
  • [4] PREVENTION OF SYMPTOMATIC RECURRENCES OF PAROXYSMAL ATRIAL-FIBRILLATION IN PATIENTS INITIALLY TOLERATING ANTIARRHYTHMIC THERAPY - A MULTICENTER, DOUBLE-BLIND, CROSSOVER STUDY OF FLECAINIDE AND PLACEBO WITH TRANSTELEPHONIC MONITORING
    ANDERSON, JL
    GILBERT, EM
    ALPERT, BL
    HENTHORN, RW
    WALDO, AL
    BHANDARI, AK
    HAWKINSON, RW
    PRITCHETT, ELC
    [J]. CIRCULATION, 1989, 80 (06) : 1557 - 1570
  • [5] THE EFFECT OF CARDIOVERSION ON MAXIMAL EXERCISE CAPACITY IN PATIENTS WITH CHRONIC ATRIAL-FIBRILLATION
    ATWOOD, JE
    MYERS, J
    SULLIVAN, M
    FORBES, S
    SANDHU, S
    CALLAHAM, P
    FROELICHER, V
    [J]. AMERICAN HEART JOURNAL, 1989, 118 (05) : 913 - 918
  • [6] DILTIAZEM AND EXERCISE PERFORMANCE IN PATIENTS WITH CHRONIC ATRIAL-FIBRILLATION
    ATWOOD, JE
    MYERS, JN
    SULLIVAN, MJ
    FORBES, SM
    PEWEN, WF
    FROELICHER, VF
    [J]. CHEST, 1988, 93 (01) : 20 - 25
  • [7] ATWOOD JE, 1987, J AM COLL CARDIOL, V10, P314
  • [8] EXERCISE HEART-RATES AT DIFFERENT SERUM DIGOXIN CONCENTRATIONS IN PATIENTS WITH ATRIAL-FIBRILLATION
    BEASLEY, R
    SMITH, DA
    MCHAFFIE, DJ
    [J]. BRITISH MEDICAL JOURNAL, 1985, 290 (6461) : 9 - 11
  • [9] INTERACTION BETWEEN DIGOXIN AND CALCIUM-ANTAGONISTS AND ANTI-ARRHYTHMIC DRUGS
    BELZ, GG
    DOERING, W
    MUNKES, R
    MATTHEWS, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (04) : 410 - 417
  • [10] BIALY D, 1992, Journal of the American College of Cardiology, V19, p41A